



7TH ANNUAL CONGRESS

Liquid Biopsy

November 1 - 3, 2025 | Orlando, USA

International Society of Liquid Biopsy
7th Annual Congress

PROGRAM BOOK

2025.islb.info

[#ISLB25](https://twitter.com/ISLB25)



What helps keep your liquid biopsy testing workflow on track?

Share your best practices!





Table of Contents

Welcome Message	4
About ISLB	5
Venue Floorplan	6
Program at a Glance	7
Full Congress Program	10
ISLB Award Lectures	20
Welcome Reception	21
Sponsors Recognition	22
Exhibit Floorplan	23
Exhibitor Listing	24
Poster Listing	32
General Information	39
Save the Date ISLB 2026	41

Welcome to the 7th Annual Congress of Liquid Biopsy

We're thrilled to have you here in Orlando for the 2025 ISLB Annual Congress, taking place November 1–3. Your presence marks a pivotal moment in the global conversation around liquid biopsy technologies and their clinical impact. This year's congress brings together a dynamic community of scientists, clinicians, industry leaders, and innovators, each contributing to the advancement of precision medicine.

Over the next few days, you'll experience a robust scientific program featuring renowned experts, groundbreaking research, and interactive sessions designed to spark collaboration across disciplines. Whether you're presenting, networking, or exploring new ideas, this congress is your platform for meaningful exchange and discovery.

Stay tuned for daily highlights, keynote sessions, and opportunities to connect with peers who share your passion and vision. We're honored to have you with us. Let's make this an unforgettable experience.

Christian Rolfo

President of ISLB on behalf
of the Executive Committee



About ISLB

ISLB was founded in 2017 in Granada, in Spain. Our aim is to join healthcare professionals, mainly oncologists and those who adopted liquid biopsies as a new clinical tool.

The International Society of Liquid Biopsy (ISLB) is the first international professional organization committed to the improvement and implementation of liquid biopsies in clinical routine practice and the promotion of a multidisciplinary approach for the diagnosis and treatment of cancer patients based on the use of liquid biopsies.



Meet the Committee of ISLB 2025

Meet the driving forces behind ISLB 2025! Our committee is made up of passionate professionals and global experts, all committed to advancing research and innovation in liquid biopsy.



Christian Rolfo
USA (ISLB President)




Maria José Serrano
Spain (ISLB Vice President)




Umberto Malapelle
Italy (ISLB Scientific Secretary)



Eloisa Jantus Lewintre
Spain (ISLB Treasurer)



David R. Gandara
USA (ISLB CMO)




Massimo Cristofanilli
USA (ISLB Past President)

Venue Floorplan

Palms Conference Center

- Registration Desk
- Exhibit & Posters, Showcase Theatre
- Main Session Room / Industry Symposia
- Meeting Rooms



Program at a Glance

Saturday, November 1, 2025

8:00 AM	New Clinical Application in Advanced Stage Cancer #1 8:00 AM - 9:30 AM
9:00 AM	
10:00 AM	Improving Sensivity in Liquid Biopsy for Early Cancer Detection 9:45 AM - 11:15 AM
11:00 AM	
12:00 PM	AM Break: Poster Session & Showcase Theatres 11:30 AM - 12:30 PM
1:00 PM	Industry Symposium by Thermo Fisher Scientific & AstraZeneca: Integrating Plasma ctDNA Into Routine Care to Optimise Outcomes in NSCLC: From Targeted Therapy Selection to Prognostication 12:30 PM - 1:30 PM
2:00 PM	Stakeholder Workshop 1:45 PM - 3:15 PM
3:00 PM	
4:00 PM	PM Break 3:15 PM - 3:45 PM
5:00 PM	Awards Lecture Location: Royal 1, 2, 3 3:45 PM - 5:15 PM
6:00 PM	Opening Ceremony 5:15 PM - 6:00 PM
7:00 PM	Welcome Reception supported by  6:00 PM - 7:30 PM
8:00 PM	
9:00 PM	

Program at a Glance

Sunday, November 2, 2025

Monday, November 3, 2025

	Industry Symposium by FT3: The Role of Liquid Biopsy in Patients' Journey: Multidisciplinary Aspects Towards Precision Oncology - A Scalable Training Approach From the FT3 Program 8:00 AM - 9:00 AM	BREAKFAST PROVIDED	8:00 AM
New Clinical Application in Advanced Stage Cancer #2 9:15 AM - 10:45 AM	AM Break: Poster Session & Showcase Theatres 9:00 AM - 10:00 AM		9:00 AM
	Preferred Orals Session 10:00 AM - 11:30 AM		10:00 AM
AM Break: Poster Session & Showcase Theatres 10:45 AM - 11:45 AM			11:00 AM
Industry Symposium by Guardant 12:00 AM - 1:00 PM	Closing Ceremony 11:30 AM - 12:30 PM		12:00 PM
			1:00 PM
Decoding the Circulating Tumor Ecosystem: Multi Analyte Liquid Biopsy Unveiling Immune Dynamics, Dormancy and Platelet Crosstalk 1:15 PM - 2:45 PM			2:00 PM
PM Break 2:45 PM - 3:15 PM			3:00 PM
Clinical Session - New Adjuvant, Adjuvant / MRD 3:15 PM - 4:45 PM			4:00 PM
			5:00 PM
Industry Symposium by Natera: Measuring What Matters: Tumor Informed MRD Testing Across Multiple Cancer Types 5:00 PM - 6:00 PM		REFRESHMENTS PROVIDED	6:00 PM
Young Career Session 6:15 PM - 7:15 PM			7:00 PM
Faculty Dinner (By Invitation Only) supported by  GUARDANT 7:30 PM - 9:00 PM			8:00 PM
			9:00 PM



REGENERON®

We aim to push the bounds of science to make

LIFE-CHANGING MEDICINES

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

Founded and led for over 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases.

Learn more at [Regeneron.com](https://www.regeneron.com) →

Follow @Regeneron



Full Congress Program

Saturday, November 1, 2025

08:00 – 09:30 New Clinical Applications in Advanced Stage Cancer #1

Location: Royal 1, 2, 3

Chair: *Daniel Stover, Luis Raez*

08:10 New Clinical Applications of Liquid Biopsy in Lung Cancer
David Gandara

08:20 New Clinical Applications of Liquid Biopsy in Breast Cancer
Eloisa Jantus Lewintre

08:40 Plasma ctDNA Monitoring in Advanced Stage Cancer
Sadakatsu Ikeda

08:50 Panel Discussion:
Daniel Stover, Noelia Tarazona, Luis Raez, David Gandara, Eloisa Jantus Lewintre, Sadakatsu Ikeda

09:45 – 11:15 Improving Sensitivity in Liquid Biopsy for Early Cancer Detection

Location: Royal 1, 2, 3

Chairs: *Clara Mayo De Las Casas, Roberto Borea*

09:55 Early Detection in NSCLC
Christian Rolfo

10:05 Tissue Agnostics Cancer Detection Through Cell-Free DNA Methylomes
Daniel De Carvalho

10:15 Fragmentomics in Early Detection of Hepatocellular Carcinoma
Victor Velculescu

10:25 ECV
Julia Burnier

10:35 ctDNA -MRD to Personalize Therapy in Non-Small Cell Lung Cancer
Atocha Romero

10:45 Panel Discussion:
Maria Serrano, Elsa Anagnostou, Clara Mayo De Las Casas, Roberto Borea, Christian Rolfo, Daniel De Carvalho, Victor Velculescu, Julia Burnier, Atocha Romero

11:30 – 12:30 AM Break: Poster Session & Showcase Theatres

Location: Exhibit & Poster Hall

11:35 **Showcase Theatre supported by Burning Rock:**
11:55 **Advancing Precision Oncology with Liquid Biopsy:**
Tumor-informed and tumor-naïve MRD Solutions

Presenter: *Yiming Guo, Translational Medicine Scientist, Burning Rock Dx*

Key Points:

- Leveraging ultra-sensitive tumor-inform MRD test to unlock deeper Insights into treatment response and patient surveillance
- Introduce Burning Rock's tumor-naïve MRD solution and explore how it can potentially accelerate ctDNA-guided clinical study development

12:05 **Showcase Theatre supported by Nuvation Bio: IBTROZI™**
12:25 **(taletrectinib): A New Treatment Option for ROS1+ NSCLC**

Presenter: *Amanda Scofield, PharmD, Executive Director, Head of Field Medical at Nuvation Bio.*

The presentation will focus on IBTROZI (taletrectinib), the recently approved ROS1 tyrosine kinase inhibitor, including a review of it's indication and registrational clinical efficacy and safety data.

12:30 – 13:30 Industry Symposium by Thermo Fisher Scientific & AstraZeneca: Integrating Plasma ctDNA Into Routine Care to Optimise Outcomes in NSCLC: From Targeted Therapy Selection to Prognostication

Location: Royal 1, 2, 3

Chair: *Bruna Pellini*

12:30 Welcome and Introductions

12:40 *Bruna Pellini*

12:40 Beyond Tissue: Practical Guidelines and Emerging Evidence for
13:00 Liquid-based Genotyping in NSCLC

Umberto Malapelle

13:00 Harnessing ctDNA Technology for Prognostication in Patients with
13:20 Early-stage NSCC

Charu Aggarwal

13:20 Question and Answers

13:25 *All Faculty*

13:25 Closing

13:30 *Bruna Pellini*

13:45 – 15:15 Stakeholder Workshop

Location: Royal 1, 2, 3

Chairs: *David Gandara, Christian Rolfo*

13:45 Panel 1: Clinical Applications

14:30 Moderator: David Gandara

Panelists: *Mary Redman, Ola Khorshid, Jean Francois Pouliot, Michal Harel, Charu Aggarwal, Edgardo Santos, Partha Das, Tasneem Habib-Ishaq*

14:30 Panel 2: Translational Science

15:15 Moderator: Christian Rolfo

Panelists: *Aya El Helali, Massimo Cristofanilli, Luca Quagliata, Annabelle Gurwitch, Lauren Leiman, Hashem Alshurafa, Amaya Gasco, Minetta Liu*

15:15 – 15:45 Coffee Break

15:45 – 17:15 Awards Lecture

Location: Royal 1, 2, 3

Chairs: *Christian Rolfo, Maria Serrano*

15:55 CSF Molecular Profiling – From Proof of Concept to Routine Clinical Procedure
Maria Arcila

16:20 Early Cancer Detection using cfDNA Fragmentomes
Victor Velculescu

17:15 – 18:00 Opening Ceremony

Location: Royal 1, 2, 3

18:00 – 19:30 Welcome Reception

Location: Exhibit & Poster Hall

Supported by



Sunday, November 2, 2025

09:15 – 10:45 New Clinical Applications in Advanced Stage Cancer #2

Location: Royal 1, 2, 3

Chairs: Yüksel Ürün, Aadel Chaudhuri

09:25 Liquid Biopsy in Sarcomas
Jonathan Trent

9:35 Epigenetics and Liquid Biopsy
Manel Esteller

9:45 Liquid Biopsy of Prostate Cancer
Francesco Pepe

9:55 Emerging role of bioinformatics in Liquid Biopsy
Joe Ibrahim

10:05 Panel Discussion:
Edgardo Santos, Enes Erul, Yüksel Ürün, Aadel Chaudhuri, Silvia Calabuig, Jonathan Trent, Manel Esteller, Joe Ibrahim, Francesco Pepe

10:45 – 11:45 AM Break: Poster Session and Showcase Theatres.

Location: Exhibit & Poster Hall

10:50 - **Showcase Theatre supported by SOPHiA GENETICS:**
11:10 **Decentralized Liquid Biopsy Testing Using MSK-ACCESS® with SOPHiA DDM™: Insights from Multi-Cancer Clinical Profiling in OncoHelix**

Presenter: *Rehan Mujeeb Faridi, Director of Molecular Diagnostics at OncoHelix*

Liquid biopsy has emerged as a powerful, non-invasive alternative to tissue-based testing for molecular profiling in oncology. Here, we present a real-world clinical validation and application of the MSK-ACCESS® assay powered with SOPHiA DDM™, a decentralized solution for circulating cell-free DNA (cfDNA) analysis from plasma, coupled with matched genomic DNA (gDNA) from white blood cells (WBCs). This approach enables robust tumor-normal comparison, improving detection accuracy by filtering out germline variants and confounding clonal hematopoiesis of indeterminate potential (CHIP)–associated mutations.

In this study, we profiled a total of 325 liquid biopsy samples, predominantly from patients with metastatic castration resistant prostate cancer (mCRPC, 85%), followed by lung cancer (6%) and other malignancies (9%). A targeted panel of 147 cancer-related genes and select non-coding regions (e.g., TERT promoter, MET exon 14 skipping) was evaluated. Most frequently observed mutations included AR (19.8%), TP53 (14.2%), ATM (6.6%), PTEN (5.2%), BRCA1/2 (4.9%), CDK12 (4.2%), and PIK3CA (3.1%). Collectively, alterations in these genes comprised 58.0% of reports, with 36.1% of cases yielding no detectable alterations. Commonly occurring CHIP mutations that would otherwise be classified as actionable variants were effectively excluded through tumor-normal comparison. CHIP mutations were frequently recognized in TP53, ASXL1, PPM1D, ATM, SF3B1, SRSF2, and U2AF1 genes.

Our experience underscores the utility of the cfDNA testing using a tumor-normal approach, particularly in patients who are ineligible for tissue biopsy or require serial monitoring. The inclusion of matched WBC DNA allows accurate discrimination of somatic versus non-tumor variants, significantly reducing the risk of false positives due to CHIP. Our experience validates the implementation of MSK-ACCESS® with SOPHiA DDM™ as a clinically informative platform for precision oncology applications across diverse cancer types.

11:20 -
11:40

**Showcase Theatre supported by Bristol Myers Squibb:
Targeted Therapies in NSCLC**

Presenter: *Dr. Martin Dietrich, Medical Oncologist, The US Oncology Network, Orlando, FL*

This presentation includes a treatment option for patients with ROS1+ NSCLC as well as a discussion of a targeted therapy for 2L KRAS G12C mutated advanced NSCLC.

12:30 – 13:30 Industry Symposium by Guardant

Location: Royal 1,2,3

Presenter: *Hashem Alshurafa*

13:15 – 14:45 Decoding the Circulating Tumor Ecosystem: Multi Analyte Liquid Biopsy Unveiling Immune Dynamics, Dormancy and Platelet Crosstalk

Location: Royal 1, 2, 3

Chairs: *Eleonora Nicolò, Konstantinos Venetis*

- 13:25 Liquid Biopsy for Monitoring Dormancy and Reactivation in Breast Cancer Brain Metastasis
Jose Javier Bravo-Cordero
- 13:35 Mapping the Circulating Immune Microenvironment for Precision Oncology
Diego De Miguel Perez
- 13:45 Biological and Clinical Impact of Direct Crosstalk Between Tumor Cells and Platelets
Maria Serrano
- 13:55 Panel Discussion:
Paraskevi Giannakakou, Anthony Lucci, Eleonora Nicolò, Konstantinos Venetis, Jose Javier Bravo-Cordero, Diego De Miguel Perez, Maria Serrano

14:45 – 15:15 Coffee Break

Location: Exhibit & Poster Hall

15:15 – 16:45 Clinical Session – New Adjuvant, Adjuvant / MRD

Location: Royal 1, 2, 3

Chairs: *Bruna Pellini*

- 15:25 Oncologist – Solid Tumors
- 15:35 Molecular Pathologist – Solid Tumors
Umberto Malapelle
- 15:45 Panel Discussion:
Maria Arcila, Natasha Leighl, Bruna Pellini, Massimo Cristofanilli, Umberto Malapelle, Eloisa Jantus Lewintre

17:00 – 18:00 Industry Symposium by Natera: Measuring What Matters: Tumor Informed MRD Testing Across Multiple Cancer Types

Location: Royal 1, 2, 3

Presenters: *Jamie McKenzie, Guru Sonpavde*

In this session, we will explore:

- The value of MRD testing across tumor types: Explore MRD testing as a tumor-agnostic tool for detecting molecular residual disease, monitoring treatment response, and predicting recurrence risk across multiple cancer types
- Evaluate clinical utility and evidence: Review recent clinical data demonstrating how MRD informs treatment decisions, supports risk stratification, and complements standard of care tools
- Apply MRD testing in practice: Discuss real-world implementation, including when to order MRD testing, how to interpret results, and how to integrate them into multidisciplinary care pathways to improve patient outcomes

18:15 – 19:15 Young Career Session: One Drop, Two Points of View: Clinical and Biological Perspectives in Liquid Biopsy

Location: Royal 1, 2, 3

Moderators: *Carolina Reduzzi, Roberto Borea*

Speakers: *Aakash Desai, Evi Giannakakou, Alessandro Russo, Diego De Miguel Perez*

Monday, November 3, 2025

08:00 – 09:00 Industry Symposium supported by FT3: The Role of Liquid Biopsy in Patients' Journey: Multidisciplinary Aspects Towards Precision Oncology - A Scalable Training Approach From the FT3 Program

Location: Royal 1, 2, 3

Moderators: *Francesco Pepe, Konstantinos Venetis*

- 08:00 - Introduction
- 08:10 *Francesco Pepe, Konstantinos Venetis*
- 08:10 - Breast Cancer Focus – Joint Session
- 08:30 *Marianna D'Ercole, Eltjona Mane*
- 08:30 - Lung Cancer Focus – Joint Session
- 08:50 *Claudia Scimone, Gianluca Russo*
- 08:50 - Discussion & Take-Home Messages
- 09:00 *Francesco Pepe, Konstantinos Venetis, Pasquale Pisapia, Mariantonia Nacchio, Giuseppina Bonizzi*

Join us for an interactive session exploring the pivotal role of liquid biopsy in precision oncology, with a focus on breast and lung cancer. Through FT3's "Precision in Practice" Program, we'll showcase a scalable, multidisciplinary training approach designed to optimize the pre-analytical phase of biomarker testing. Featuring clinical case discussions and technical deep dives, this session highlights the critical collaboration between pathologists, oncologists, lab technicians, and nurses in ensuring the accuracy and reliability of molecular testing. Gain valuable insights into integrating liquid and tissue biopsy workflows, overcoming challenges in serial testing, and advancing patient outcomes through global, collaborative training.

09:00 – 10:00 AM Break: Poster Session & Showcase Theatre

Location: Exhibit & Poster Hall

09:05 – 09:25 **Showcase Theatre supported by OncoHost: Biological Insights From Plasma Proteomics: Uncovering Drivers of Treatment Response and Toxicity**

Presenter: *Michal Harel, PhD, VP Translational Medicine, OncoHost*

Plasma proteomics offers a minimally invasive approach to characterize systemic biological processes associated with cancer therapy. In this study, we performed large-scale proteomic profiling of plasma samples collected from patients across multiple cancer types and treatment modalities. Using computational analyses and machine learning, we identified distinct protein signatures linked to clinical benefit from immunotherapy, chemotherapy, and targeted treatment, each with a unique biological footprint. Beyond treatment efficacy, our analyses revealed proteomic patterns associated with adverse events, suggesting that circulating proteins can provide mechanistic insights into therapy-related toxicities.

Integration of proteomic data with clinical outcomes underscores the dual role of plasma biomarkers in guiding therapeutic decision-making and anticipating toxicity risks. These findings demonstrate the potential of plasma proteomics to serve as a real-time, systems-level tool for understanding treatment biology, ultimately supporting the development of more precise and individualized strategies in oncology.

10:00 – 11:30 Preferred Oral Session

Location: Royal 1, 2, 3

Chairs: Alessandro Russo, Giovanni Nigita

- 10:10 High Performance of Cancer Detection With Using Single-Strand Circulating DNA Fragment End Motif Analysis
A.R. Thierry
- 10:15 Circulating Tumor DNA (ctDNA) Detectable in Buffy Coat DNA (bcDNA) Can Resemble Clonal Hematopoiesis With Potential Biological and Clinical Implications
Pashtoon Kasi
- 10:20 Ignacio Wistuba - Abstract Discussant
- 10:30 ERBB2 Mutation Landscape in Metastatic Invasive Lobular (ILC) and No Special Type (NST) Breast Cancer Revealed by Longitudinal Liquid Biopsy
Daisong Liu

- 10:35 Clinical Utility of Soluble Immune Mediators and cfDNA in Endometrial Cancer
Silvia Calabuig
- 10:40 Bruna Pellini – Abstract Discussant
- 10:50 Longitudinal Monitoring of ctDNA Tumor Fraction Dynamics for Early Detection of Chemotherapy Resistance
Roberto Borea
- 10:55 Multimodal ctDNA Profiling Identifies Fragmentomics and Tumor Fraction As Independent Prognostic Biomarkers of Ovarian Cancer Survival: The MITO-16a/MANGO-OV2a Trial Experience
Sergio Marchini
- 11:00 Aadel Chaudhuri - Abstract Discussant
- 11:10 Q&A

11:30 – 12:30 Closing Ceremony

Location: Royal 1, 2, 3

ISLB Award Lectures



Research Award Maria Arcila



Dr. Arcila received her MD degree from the University of Pittsburgh School of Medicine and completed postgraduate training in Anatomic and Clinical Pathology at Madigan Army Medical Center, followed by subspecialty fellowships at Memorial Sloan Kettering Cancer Center (MSKCC) in Molecular Genetic Pathology and Hematopathology. She has served as Director of the Molecular Pathology Laboratory at MSKCC and is currently the Deputy Chief of the Molecular Diagnostic Service at the same institution. Dr. Arcila's research work highlights therapeutic and prognostic molecular markers in solid tumors and hematologic malignancies and her work focuses on the expansion, validation, and implementation of clinical tests to optimize precision medicine.

Lifetime Achievement Award Victor Velculescu



Dr. Victor E. Velculescu is a global leader in cancer genomics and liquid biopsy innovation. He led the first genome-wide sequencing of human cancers, identified key mutations like PIK3CA, and helped develop FDA-approved therapies and diagnostics. His team pioneered whole-genome analysis of cell-free DNA, enabling DELFI—a non-invasive blood test for early cancer detection. He is Professor and Co-Director of Cancer Genetics at Johns Hopkins, with degrees from Stanford and Johns Hopkins. A founder of DELFI Diagnostics and Personal Genome Diagnostics, he has received major honors including the AACR Award, Paul Marks Prize, and Precision Medicine Pioneer Award. He holds over 500 patents and serves on multiple scientific advisory boards.



Welcome Reception

Supported by



Date: Saturday, November 1

Time: 6:00 PM – 7:30 PM

Location: Palms Conference Center – Majestic Ballroom

Access: Complimentary for all registered attendees.
Tickets required for guests.

Join us this evening at the official ISLB 2025 Welcome Reception. After the first full day of the congress, come for a drink and some light food and catch up with old friends and colleagues and meet new ones as well as say hi to our exhibitors!

Exhibit & Poster Hall

Location: Palms Conference Center – Majestic Ballroom

Saturday, November 1

10:00 AM – 4:00 PM

6:00 PM – 7:30 PM (Welcome Reception)

Sunday, November 2

10:00 AM – 4:00 PM

Monday, November 3

8:30 AM – 10:30 AM



7TH ANNUAL CONGRESS
Liquid Biopsy
November 1 - 3, 2025 | Orlando, USA

Program Book

2025.islb.info

Thank you to Our Sponsors

PLATINUM

ThermoFisher
SCIENTIFIC

GOLD

Johnson&Johnson

SILVER



BRONZE



SUPPORTERS



**FACULTY DINNER
SUPPORTER**

**MOBILE APP
SUPPORTER**

**LANYARD
SUPPORTER**



Johnson&Johnson



**POSTER SESSION
SUPPORTER**

**WELCOME RECEPTION
SUPPORTER**




7TH ANNUAL CONGRESS
Liquid Biopsy
November 1 - 3, 2025 | Orlando, USA

Program Book

2025.islb.info

Exhibit Floorplan



EXHIBITOR

1Cell.AI	307
Actorius Innovations and Research Co	308
Agilent Technologies	206
ANGLE	107
BillionToOne	303
Bio-Rad Laboratories	408
Boehringer Ingelheim	109
Burning Rock Dx	200
Caris Life Sciences®	400
Exact Sciences	309
Foundation Medicine	201
GT Molecular, Inc.	301

EXHIBITOR

Menarini Silicon Biosystems	103
Natera	101
Norgen Biotek Corp.	208
Nuvation Bio	209
Omega Bio-Tek	203
OncoHost	300
Portamedic	402
SAGA Diagnostics	406
SOPHiA GENETICS	302
STEMCELL Technologies Inc.	306
Tempus	207
Tethis S.p.A.	202

Exhibitor Listing

1Cell.Ai

Booth #307



1Cell.Ai, based in Foster City, California, is at the forefront of precision oncology, driving personalized cancer therapy with its innovative single cell multi-omics platform combining cutting-edge molecular science with advanced AI technology. This platform delivers real-time information allowing for the comprehensive analysis of individual cancer cells across multiple molecular levels, including genomics, transcriptomics, proteomics, and epigenomics. This technology provides deep insights into tumor heterogeneity, enabling the identification of rare cell populations that may drive metastasis or resistance to therapy, and tailoring treatments to improve patient outcomes.

1cell.ai

Actorius Innovations and Research Co

Booth #308



Actorius Innovations and Research Pvt. Ltd. is an Indo-US oncology company with laboratories in Pune (India) and Pasadena (USA). The company specialises in Circulating Tumor Cell (CTC) technologies, developing next-generation platforms with diagnostic and theranostic applications, enabling real-time cancer detection, disease monitoring, and therapeutic interventions in precision oncology.

actorius.co

Agilent Technologies

Booth #206



Agilent Technologies

Agilent is a global leader in life sciences and diagnostics. Employing approximately 18,000 people worldwide, Agilent operates in six key markets. Its mission is to improve quality of life through scientific innovation. With facilities and sales offices worldwide, Agilent delivers high-quality solutions to customers in 110 countries.

agilent.com



ANGLE

Booth #107

Circulating tumour cells (CTCs) can provide critical insights in cancer research by enabling dual analysis of CTC-DNA and ctDNA from a single blood tube, as well as RNA and protein analyses that advance precision oncology. ANGLE's proprietary Parsortix® system offers an optimal solution for capturing and harvesting CTCs directly from whole blood, supported by over 100 peer-reviewed publications across 42 independent cancer centres and 24 cancer types. Alongside supplying the Parsortix system for research use, ANGLE delivers specialised clinical and translational services through its accredited laboratories, supporting biomarker discovery, drug development and customised liquid biopsy assay validation.

angleplc.com



BillionToOne

Booth #303

Northstar by BillionToOne is a blood-based liquid biopsy platform that delivers ultra-sensitive genomic and methylation analysis to support personalized cancer care. Powered by proprietary QCT™ technology, Northstar Select® provides comprehensive genomic profiling to guide therapy selection, while Northstar Response® enables real-time monitoring of treatment efficacy through tumor-specific methylation tracking. Together, they offer a seamless, non-invasive solution for oncology practices—delivering singlemolecule precision and faster insights to help clinicians make more informed decisions.

northstaronc.com



Bio-Rad Laboratories

Booth #408

Bio-Rad offers the Genesis system for isolation of rare cells from liquid biopsy, including circulating tumor cells (CTCs). Alongside the ddSEQ for scRNA-seq or one of Bio-Rad's best-in-class ddPCR systems, these platforms empower researchers to capture scarce populations, resolve cellular heterogeneity, and unlock insights across oncology, immunology, and translational research.

bio-rad.com



Boehringer Ingelheim

Booth #109

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

boehringer-ingelheim.com



Burning Rock Dx

Booth #200

Burning Rock Dx (NASDAQ: BNR) is a global diagnostics company focusing on applying next-generation sequencing (NGS) technology in precision oncology. Guided by the mission of “Guard Life via Science,” Burning Rock offers solutions covering the entire precision oncology development cycle through an internally developed NGS-based assay portfolio for both tissue and blood samples, along with a robust in-house database to help facilitate clinical trial studies and research. Burning Rock provides dedicated services to pharmaceutical partners, encompassing genomic data solutions, clinical trial solutions, precision patient recruitment, and companion diagnostics (CDx) development and commercialization.

brbiotech.com



Caris Life Sciences®

Booth #400

Caris Life Sciences® is a leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease.

carislifesciences.com

EXACT SCIENCES

Exact Sciences

Booth #309

Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.

exactsciences.com/



Foundation Medicine

Booth #201

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action as we work to transform cancer care.

foundationmedicine.com



GT Molecular, Inc.

Booth #301

GT Molecular provides high-performance, ultrasensitive digital and Real-Time PCR (RUO) assays for pathogen quantification, advancing cancer research, gene therapy quantification, and performing minimal residual disease (MRD) monitoring and surveillance. Our multiplex oncology and vector copy number (VCN) assay kits are optimized and validated using real patient samples, providing high-performance, easy-to-use results with all primers, probes, and controls included. Sample logistics management, PCR and NGS testing services are also available. Our customers include universities, hospitals, government entities, public health and commercial testing laboratories, biopharma and more.

gtmolecular.com

Menarini Silicon Biosystems

Booth #103



Menarini Silicon Biosystems (MSB) is the only CLIA lab that offers circulating tumor cell (CTC) enumeration and phenotyping with CellSearch® as well as comprehensive genomic profiles of tumor cell-free DNA and RNA (cfDNA/RNA) with MenariniSearch. CellSearch® is the Gold Standard of CTC technology offering a minimally invasive approach to follow your cancer patient's journey. MenariniSearch detects a broader range of genetic alterations, discovering novel biomarkers and therapeutic targets. MenariniSearch tests use NGS powered by AI and are available for most cancers. MSB's tests are CLIA/CAP ISO15189 accredited LDTs can be performed on peripheral blood, cerebrospinal fluid, tissue, and bone marrow.

siliconbiosystems.com

Natera

Booth #101



Signatera is a custom-built circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and treatment monitoring and in patients previously diagnosed with cancer. Signatera's performance has been clinically validated in multiple solid tumors including colorectal, breast, and bladder cancers as well as for immunotherapy response monitoring.

natera.com

Norgen Biotek Corp.

Booth #208



At Norgen Biotek Corp., we deliver innovative solutions for sample collection, preservation, extraction, and detection, empowering groundbreaking discoveries. Backed by expert support and trusted global collaborations, we provide reliable products and guidance to help you achieve consistent results throughout your scientific journey.

norgenbiotech.com



Nuvation Bio

Booth #209

Nuvation Bio is a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology. Our vision is to significantly change the treatment of cancer by developing novel and differentiated medicines that provide truly meaningful improvements in quality of life and survival for people around the world.

nuvationbio.com



Omega Bio-Tek

Booth #203

For over 25 years, Omega Bio-tek has been an industry-leading provider of DNA/RNA purification kits and equipment for clinical, biotechnology, and genomics research. Operating under ISO 9001:2015 and ISO 13485:2016 certification, Omega Bio-tek provides a diversified product portfolio for low- and high-throughput purification of high-quality nucleic acids from a wide variety of sample types. Omega Bio-tek's products and automation support services are used in thousands of universities and research laboratories in over 100 countries worldwide. Visit <https://www.omegabiotek.com> for more information on our products and services.

omegabiotek.com



OncoHost

Booth #300

OncoHost is transforming the approach to precision medicine with PROphet®, a plasma-based, proteomic pattern analysis tool. Its initial offering, the PROphetNSCLC™ test uses one blood sample to guide first-line immunotherapy decisions in NSCLC, delivering personalized treatment insights that help physicians optimize care and improve patient survival outcomes.

oncohost.com

Portamedic

Booth #402



Portamedic completes nationwide mobile phlebotomy services. Each year we complete over 2 million mobile blood draws. With coverage in all 50 states and Puerto Rico we can see your patients anytime and anywhere. We work with many companies in the liquid biopsy and cancer surveillance spaces.

portamedic.com

SAGA Diagnostics

Booth #406



SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company's flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer. SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types.

sagadiagnostics.com

SOPHiA GENETICS

Booth #302



SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.

sophiagenetics.com



STEMCELL Technologies Inc.

Booth #306

STEMCELL Technologies supports liquid biopsy research with reproducible whole blood processing and preanalytical workflow solutions. From sample preparation, including cell and extracellular vesicle (EV) isolation, to scalable automation with RoboSep™, our tools streamline workflows and ensure consistent results. Visit Booth #306 or www.STEMCELL.com to learn more.

stemcell.com

"TEMPUS

Tempus

Booth #207

Tempus is a technology company leading the adoption of AI to advance precision medicine and patient care.

tempus.com



Tethis S.p.A.

Booth #202

Tethis S.p.A., an Italian diagnostic company, is introducing the first automated platform that standardizes plasma and cytology sample preparations for multiomics liquid biopsy.

tethis-lab.com

Poster Listing

supported by



- PP.02: (88)** **An Ultrasensitive Multiplexed Digital PCR Assay for Detecting ESR1 Mutations in Plasma-Derived Cell-Free DNA**
Stephanie Barbari, United States
- PP.03: (103)** **Prognostic and Diagnostic Role of Circulating Tumor DNA (ctDNA) in High-risk Melanoma Patients: A Systematic Review and Meta-analysis**
Pedro C. A. Reis, Brazil
- PP.04: (60)** **Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO I PanTracer LBx assay**
Amber Chevalier, United States
- PP.05: (57)** **Validation of NEO PanTracer LBx, a liquid biopsy, precision oncology pan-solid tumor comprehensive genomic profiling assay (CGP)**
Amber Chevalier, United States
- PP.06: (84)** **Real-world utilization of tissue-free circulating tumor DNA (ctDNA) monitoring in cancer patients receiving immune checkpoint inhibitors (ICI)**
Merrida Childress, United States
- PP.07: (113)** **Analysis of the Circulating Cell-free DNA Fragment Size Biomarker in Patients with Metastatic Breast Cancer**
Ricardo Chinchilla-Monge, Costa Rica
- PP.08: (70)** **Platelet gene expression profiling as a liquid biopsy tool to monitor Immunotherapy resistance in advanced NSCLC patients**
Simona Coco, Italy
- PP.09: (30)** **Expanding Access to Precision Oncology in Underserved Populations: Integrating Liquid Biopsy into a Statewide Lung Cancer Initiative**
Aakash Desai, United States
- PP.10: (56)** **Implementing Liquid Biopsy Testing for Breast Cancer Patients in Wales within the National Health Service (NHS)**
Rachel Dodds, United Kingdom

- PP.11: (54) BRCA Profiling in Metastatic Prostate Carcinoma: A Liquid Biopsy Concordance Study**
Ramin Dowlati, United States
- PP.12: (114) Extent of ctDNA Tumor Fraction Reduction as a Predictor of Chemotherapy Outcomes in Advanced Solid Tumors**
Francesco Drago, United States
- PP.13: (69) Liquid Biopsy Utility in Deficient Mismatch Repair Non-Small Cell Lung Cancer: Insights from a Prospective Real-World Study**
Aya El Helali, Hong Kong
- PP.14: (49) Tumor-Informed Circulating Tumor DNA (ctDNA) in Advanced NSCLC Treated with Pembrolizumab ± Chemotherapy**
Diego Enrico, Argentina
- PP.15: (22) Performance Characterisation of a Novel Whole Genome Sequencing Informed MRD Assay**
Tim Forshaw, United Kingdom
- PP.16: (45) Liquid Biopsy Innovation: ctDNA Accurately Detects Systemic Recurrence in Lung Cancer with Strong Concordance to Imaging**
Michael Galo, United States
- PP.17: (14) Genomic Landscape and Clinical Value of Circulating Tumor DNA Tumor Fraction Across Lines of Therapy in Patients with Advanced NSCLC**
Amaya Gascó, United States
- PP.18: (97) Tumor-informed Assessment of Minimal Residual Disease Using Circulating Tumor DNA (ctDNA) in Breast and Colorectal Cancers**
Gargi D Basu, United States
- PP.19: (67) Plasma and Pleural Effusion as reflective mirrors of the Immune Landscape in two histotypes of Pleural Mesothelioma**
Carlo Genova, Italy
- PP.20: (52) Liquid Biopsies of Lung Cancer and Next Generation Sequencing at Sub-Saharan Africa Sites (LUNGS@AFRICA)**
Nadia Ghazali, Canada
- PP.21: (102) Plasma Proteomics as a Systemic Monitoring Approach in NSCLC Immunotherapy: Comparative Analysis with ctDNA**
Michal Harel, United States
- PP.22: (73) Prevalence and Characterization of ESR1 Alterations Detected with an Ultra-Sensitive, Liquid-Only CGP Assay in a Large Breast Cancer Cohort**
Lenny K. Hong, United States
- PP.23: (13) Repositioning ctDNA as a Real-Time Clinical Compass: A Meta-Analysis of 14,000 Patients Across 42 Studies**
Mohamed Tharwat Kamouna, Egypt

- PP.24: (34) Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients**
Jayant Khandare, India
- PP.25: (38) Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate**
Jayant Khandare, India
- PP.26: (35) Association of Circulating Tumor Cell Dynamics in Pre and Post-Surgical Breast Cancer Patients**
Jayant Khandare, India
- PP.27: (33) PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients**
Jayant Khandare, India
- PP.28: (9) Role of Circulating miR-425-5p as Liquid Biopsy Biomarker for Prediction of Prognosis in Metastatic Non-Small Cell Lung Cancer**
Ola khorshid, Egypt
- PP.29: (96) Real-world Utilization of Tissue-free Circulating Tumor DNA (ctDNA) Monitoring Across Tumor and Therapy Types**
Merrida Childress, United States
- PP.30: (109) Clinical Relevance of Circulating Myeloma Cell Quantification and Multiple Myeloma Staging System**
박사 Jihyun Lee, Republic of Korea
- PP.31: (110) Detection of AR-V7 in Circulating Tumor Cells Correlates with Therapeutic Response in Metastatic Prostate Cancer**
박사 Jihyun Lee, Republic of Korea
- PP.32: (25) Cell-free DNA Methylation Signature-based Risk Prediction Model for Managing Pancreatic Ductal Adenocarcinoma Patients**
Ashish Manne, United States
- PP.33: (95) Is CTC PDL-1 Expression Predictive of Response after Neoadjuvant Immunotherapy in Stage IIB-IV Melanoma?**
Megan McClanahan, United States
- PP.34: (55) QuicDNA Max: A Real-World Platform Study of Circulating Tumour DNA Testing Across Multiple Tumour Types in NHS Wales**
Magdalena Meissner, United Kingdom
- PP.35: (43) Circulating Tumor Dna Profiling in Metastatic Breast Cancer Under Antibody–Drug Conjugates: a US Monocentric Retrospective Study.**
Eleonora Nicolò, United States
- PP.36: (111) ctDNA clearance of epigenetic regulators and HRR mutations predicts immunotherapy response in advanced head and neck cancer.**
Atul Bharde, India

- PP.37: (112) Oncogenic Driver Persistence in Liquid Biopsies As Predictor Outcomes in TKI Treated Non-Small Cell Lung Cancer**
Rodrigo Paredes, United States
- PP.38: (83) Detection and Monitoring ALK Gene Alterations through Liquid Biopsy in Advanced NSCLC Treated with Alectinib: Preliminary TANGIBLE Study Results**
Francesco Pepe, Italy
- PP.39: (93) ALK-PATHFINDER: interim results of liquid biopsy (LB) monitoring in ALK-positive NSCLC with comprehensive analysis of resistance and clonal hematopoiesis (CH)**
Santiago Ponce Aix, Spain
- PP.40: (86) Pan-Tumor Real-World Liquid Biopsy (LB) in Molecular Tumor Boards (MTB): Clinical Impact of Systematic Clonal Hematopoiesis (CH) Filtering (PRECISO Program)**
Santiago Ponce Aix, Spain
- PP.41: (66) Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types**
Christopher G. Smith, United Kingdom
- PP.42: (92) Clinical utility of liquid biopsy in glioblastoma multiforme patients**
Pavel Stejskal, Czech Republic
- PP.43: (89) Plasma genotyping to identify novel resistance variants in advanced NSCLC(DISCOVER): Non-AGA report**
Berenice Urtecho Suarez, Canada
- PP.44: (42) Utility of liquid biopsy for detecting actionable mutations and co-alterations in 315 cancer patients**
GRR Vittala, India
- PP.45: (26) CTC-EXPRESS: A prospective observational study for CTC biomarker Expression and cfDNA/cfRNA assessment in metastatic breast cancer**
Marija Balic, United States
- PP.46: (74) Concordance of CTCs and cfDNA with Tissue Biopsy using See.d® and SBS Slides: A Feasibility Study in Metastatic Breast Cancer**
Chiara Luise, Italy
- PP.47: (19) Enrichment of Brain Tumor-Derived ctDNAs and MicroRNAs in Blood Circulation in Patients Using Sonobiopsy**
Jinyun Yuan, United States
- PP.48: (40) Circulating immune signatures as predictors of immunotherapy response in non-small cell lung cancer**
Silvia Calabuig-Fariñas, Spain
- PP.49: (53) Searching for progression-relevant circulating tumor cells in tumor-draining and peripheral blood of prostate and renal cancer patients**
Natalia Bednarz-Knoll, Poland

- PP.50: (51) Analytical Performance of Agilent Avida Duo with Custom Multiomic Reference Standards**
Carole Durand, United States
- PP.51: (94) Real-World Comparison of Liquid and Tissue Biopsy NGS for Actionable Mutations in Advanced NSCLC: Clinical Utility and Implications in Argentina**
Diego Enrico, Argentina
- PP.52: (98) NOTCH and CTNNB1 expression variability and relapse of breast cancer in high-risk groups**
Ana Maria Espinosa, Mexico
- PP.53: (59) A Plasma Proteomics Test Predicts Immunotherapy Benefit in NSCLC Independent of Genomic Alterations**
Michal Harel, United States
- PP.54: (91) Improved detection of brain cancer-soluble biomarkers with closed-loop focused ultrasound**
Victor Menezes, United States
- PP.55: (32) Application of LEGENDplex™ multiplex immunoassays for immune profiling in urothelial cancer**
Esther Montesinos, Spain
- PP.56: (11) ALMA platform: a Pan-cancer agnostic multi-modal liquid biopsy approach for enhanced MRD detection and therapy monitoring**
Lara Paracchini, Italia
- PP.57: (87) Breast Cancer Actionable Mutation Panel Tracks Clinically Relevant Genetic Variants In Plasma Alongside The Research Use Only (RUO) Signatera Assay**
Alison Parisian, United States
- PP.58: (64) Lung Cancer Detection via Nasal Swab cfDNA and mFAST-SeqS Analysis - A Proof-of-Concept Study**
Roberta Gatta, Italy
- PP.59: (104) Early Detection of Breast Cancer Through miRNAs Expression in Liquid Biopsy: Study in the Peruvian Population**
Señora DIANA JESUS ARENAS MACHACA, Peru
- PP.60: (81) Development of a Novel Digital PCR Multiplex Test for Improved Ovarian Cancer Disease Monitoring**
Shannon Beattie, United Kingdom
- PP.61: (75) Breast cancer development risk: a novel signature based on EV-miRNAs from the EsomirR Study**
Barbara Cardinali, Italy

- PP.62: (77) PanGIA Analysis System, a Novel Machine Learning Platform for Non-Invasive Diagnosis of Multiple Cancers**
Robert Cardwell, United States
- PP.63: (47) Label-free electrochemical biosensor for saliva and plasma detection of VGFR in breast cancer patients**
Ana Maria Espinosa, Mexico
- PP.64: (27) High-Volume cfDNA Extraction Enables Rare Variant Recovery in Liquid Biopsy for Early Cancer Detection**
Nafiseh Jafari, United States
- PP.65: (31) Detection of Tumor-Specific Mutations in Plasma Utilizing an Optimized Cell-Free DNA Extraction Workflow**
Anagha Kadam, United States
- PP.66: (41) Reproducibility study of miRNAs for BlaDimiR and BlaDimiRplus clinical trials using urine samples from bladder cancer patients**
Álvaro Martín De Bernardo, Spain
- PP.67: (36) A Single-Tube Solution for Enhanced Multi-Analyte Stability in Liquid Biopsy: TAG FLEX-LB BCT**
Emily Medina, United States
- PP.68: (85) Fragmentomics enhances tumor-naïve aneuploidy detection from plasma whole genome sequencing**
Abhijna K. Reddy, United States
- PP.69: (78) PanGIA Analysis System Is a Novel Machine Learning Framework for Non-Invasive Rare Disease Diagnosis Using Urinary Biomolecular Signatures**
Abhignyan Nagesetti, United States
- PP.70: (79) Cerebrospinal Fluid-Based Traumatic Brain Injury Diagnostic Enabled by PanGIA Analysis System, a Novel Machine Learning Platform for Biomolecular Pattern Recognition**
Obdulio Piloto, United States
- PP.71: (80) PanGIA Analysis System Utilizes Novel Biomolecular Profiling + Machine Learning to Detect Analytes Associated with Parkinson's Disease from Urine**
Obdulio Piloto, United States
- PP.72: (28) Evaluation of Circulating Tumor Cell isolation methods in advanced Urothelial Carcinoma patients**
Ignacio Arévalo Reina, Spain
- PP.73: (16) The RI-MUHC Circulating Biomarkers in Health & Disease Network: Advancing Translational cfDNA Research Through an Interdisciplinary Framework**
Julia Burnier, Canada

- PP.74: (62) Genomic Profiles of Early-Stage Non-Small Cell Lung Cancer Patients, and Association with Pre-Treatment Blood Circulating Tumour DNA Detection and Levels**
Clodagh Murray, Ireland
- PP.75: (119) Implementing liquid biopsy testing for BRCA1/2 alterations in metastatic castration resistant prostate cancer patients: experience from Italian referral institution**
Mariantonia Nacchio, Italy
- PP.76: (37) A Novel Mouse Model for Tissue-Specific Quantification of Circulating Extracellular Vesicles**
Kartik Nimkar, United States
- PP.77: (39) Comparative evaluation of Circulating Tumor Cell (CTC) enrichment strategies in lung and breast cancers**
Carlos Pedraz Valdunciel, United States
- PP.78: (120) Profiling cfDNA fragmentation profile in ESR1 mutant HR+/HER2- Breast cancer patients: a proof of concept trial**
Gianluca Russo, Italy
- PP.79: (118) Multi-Omic Profiling of Plasma Samples from p.G12C positive NSCLC Patients**
Claudia Scimone, Italy
- PP.80: (117) Integrating cfDNA Liquid Biopsy into Public Healthcare: Interim Findings from the Andalusian LOLA Project**
Maria Serrano, Spain
- PP.81: (17) A new pathogenic paradigm: Netosis, microclots and circulating DNA in inflammatory diseases**
A.R. Thierry, France
- PP.82: (116) Digital PCR Assay for the Simultaneous Detection of Mutations and DNA Methylation Markers in Melanoma**
Paul van der Leest, Netherlands

General Information

Access/Security

Name Badges will be provided to all delegates and participants and can be picked up at the ISLB 2025 Registration Desk. Please wear and ensure your name badge is visible at all times as it is your admission pass to all sessions, the Exhibit & Poster Hall and social events. Delegates will not be able to access the congress meeting space without their badge. There is a USD 25.00 reprint fee for any lost or misplaced badges.

Official Language

The official language of the ISLB 2025 Congress is English. All sessions will be conducted in English.

Lost Property

Please report any lost or unattended items immediately to the ISLB 2025 Registration Desk. Should you lose anything while at the ISLB 2025 Congress, please enquire at the Registration Desk where any recovered lost property will be held. At the end of the congress, all unclaimed lost and found items will be given to The Doubletree by Hilton Orlando at Seaworld.

Refreshment Breaks

Location: Palms Conference Center – Majestic Ballroom

Saturday, November 1	11:15 AM – 12:15 PM (AM Coffee Break and Poster Viewing) 3:15 PM – 3:45 PM (PM Coffee Break)
Sunday, November 2	10:45 AM – 11:45 PM (AM Coffee Break and Poster Viewing) 2:45 PM – 3:15 PM (PM Coffee Break)
Monday, November 3	9:00 AM – 10:00 AM (AM Coffee Break and Poster Viewing)

Registration Desk

Location: Palms Conference Center – Majestic Foyer

Saturday, November 1	7:00 AM – 7:00 PM
Sunday, November 2	7:00 AM – 6:30 PM
Monday, November 3	8:00 AM – 12:00 PM

WiFi

Network: ISLB2025
Password: islb-2025




Get the ISLB 2025 Mobile App



App Store



Google Play



Mobile App supported by **Johnson&Johnson**

Disclaimer

All reasonable endeavors will be made to hold the ISLB 2025 Congress and to present the program as scheduled under circumstances which assure the comfort and safety of the Congress Participants. However, the ISLB and its branches, and their respective directors, officers, employees, representatives or agents, shall not be liable in any manner whatsoever to any person as a result of the cancellation of the Congress or any of the arrangements, programs or events connected therewith; nor shall any of the foregoing entities or persons be liable in any manner whatsoever for any loss, injury, damage or inconvenience which may be suffered by any person while travelling to or from, or during such person's presence in, the United States in connection with the Congress. Participants are advised to consider procuring their own insurance against any such occurrences.



7TH ANNUAL CONGRESS
Liquid Biopsy
November 1 - 3, 2025 | Orlando, USA

Program Book

2025.islb.info



8TH ANNUAL CONGRESS
Liquid Biopsy
November 7-9, 2026 | Madrid, Spain

See you at
ISLB 2026 in Madrid, Spain!
November 7-9, 2026

